In two PDX models (AML1: 50-year-old female with NMP1 mutated, FLT3-ITD+, and CEBPA mutated AML; AML2: 73-year-old male with NMP1 mutated and FLT3-ITD+ AML), 3 mg/kg of Cy3-MTL-CEBPA was injected intravenously, and 4 hours later, the delivery to leukemic cells within the bone marrow and spleen was quantified using Cy3 fluorescence (MFI) (Figure S3). This evidence concerns the gene CEBPA and acute myeloid leukemia.